Patents by Inventor Michael Wermann
Michael Wermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210198189Abstract: The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin ? and/or ?, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin ? and/or ?, and compounds and pharmaceutical compositions for use in such methods.Type: ApplicationFiled: March 8, 2021Publication date: July 1, 2021Applicant: Vivoryon Therapeutics AGInventors: Michael Wermann, Mirko Buchholz, Hans-Ulrich Demuth, Daniel Ramsbeck, Dagmar Schlenzig, Stephen Schilling
-
Patent number: 10975019Abstract: The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin ? and/or ?, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin ? and/or ?, and compounds and pharmaceutical compositions for use in such methods.Type: GrantFiled: April 18, 2017Date of Patent: April 13, 2021Assignee: Vivoryon Therapeutics AGInventors: Michael Wermann, Mirko Buchholz, Hans-Ulrich Demuth, Daniel Ramsbeck, Dagmar Schlenzig, Stephen Schilling
-
Publication number: 20190127317Abstract: The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin ? and/or ?, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin ? and/or ?, and compounds and pharmaceutical compositions for use in such methods.Type: ApplicationFiled: April 18, 2017Publication date: May 2, 2019Inventors: Michael Wermann, Mirko Buchholz, Hans-Ulrich Demuth, Daniel Ramsbeck, Dagmar Schlenzig, Stephen Schilling
-
Patent number: 8889709Abstract: The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase-like protein (QPCTL), and the use thereof for the treatment and/or prevention of an inflammatory disease or disorder selected from the group consisting of (a) chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis; (b) other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis, Guillain-Barré syndrome, chronic inflammatory demyelinizing polyradiculoneuropathy and multiple sclerosis; (c) neuroinflammation; and (d) neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, and Familial Danish Dementia, which may result from neuroinflammation.Type: GrantFiled: September 4, 2009Date of Patent: November 18, 2014Assignee: Probiodrug AGInventors: Hans-Ulrich Demuth, Stephan Schilling, Michael Wermann, Holger Cynis, Astrid Kehlen, Daniel Friedrich, Torsten Hoffmann, Kathrin Gans, Jens-Ulrich Rahfeld, Ulrich Heiser, Michael Almstetter, Robert Sommer, Ulf-Torsten Gaertner, Antje Hamann, Michael Thormann, Andreas Treml
-
Patent number: 8859250Abstract: Novel crystal structures of human and murine glutaminyl cyclase (QC, EC 2.3.2.5), methods of preparing the crystals, as well as the use of said crystal structures for identifying inhibitors of human and murine glutaminyl cyclase.Type: GrantFiled: February 26, 2013Date of Patent: October 14, 2014Assignee: Probiodrug AGInventors: Stephan Schilling, Jens-Ulrich Rahfeld, Birgit Koch, Michael Wermann, Christoph Parthier, David Ruiz-Carillo, Milton T. Stubbs
-
Patent number: 8741614Abstract: A crystal comprising human isoglutaminyl cyclase having a characterized space group of P1211 and unit cell dimensions of +/?5% of a=126.51 ?, b=109.68 ?, c=159.53 ?, ?=90.0°, ?=104.9° and ?=90.0°.Type: GrantFiled: October 28, 2011Date of Patent: June 3, 2014Assignee: Probiodrug AGInventors: Anett Stephan, Stephan Schilling, Jens-Ulrich Rahfeld, Michael Wermann, Christoph Parthier, Hans-Ulrich Demuth, David Ruiz-Carillo, Milton T. Stubbs
-
Patent number: 8409837Abstract: A novel crystal structures of human and murine glutaminyl cyclase (QC, EC 2.3.2.5), methods of preparing the crystals, as well as the use of said crystal structures for identifying inhibitors of human and murine glutaminyl cyclase.Type: GrantFiled: August 19, 2011Date of Patent: April 2, 2013Assignee: Probiodrug AGInventors: Stephan Schilling, Jens-Ulrich Rahfeld, Birgit Koch, Michael Wermann, Christoph Parthier, David Ruiz-Carillo, Milton T. Stubbs
-
Publication number: 20130052203Abstract: A double transgenic non-human animal, in particular a transgenic mouse encoding Qpct proteins, which have been implicated in Qpct-related diseases, and Amyloid Precursor Protein (APP). Also provided are cells and cell lines comprising transgenes encoding for Qpct and APP. Also provided are methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.Type: ApplicationFiled: August 10, 2012Publication date: February 28, 2013Applicant: PROBIODRUG AGInventors: Sigrid Graubner, Wolfgang Jagla, Stephan Schilling, Holger Cynis, Hans-Ulrich Demuth, Torsten Hoffmann, Michael Wermann, Katrin Schulz, Christoph Baeuscher, Stefanie Kohlmann
-
Publication number: 20120108449Abstract: A crystal comprising human isoglutaminyl cyclase having a characterised space group of P1211 and unit cell dimensions of +/?5% of a=126.51 ?, b=109.68 ?, c=159.53 ?, ?=90.0°, ?=104.9° and ?=90.0°.Type: ApplicationFiled: October 28, 2011Publication date: May 3, 2012Applicant: PROBIODRUG AGInventors: Anett Stephan, Stephan Schilling, Jens-Ulrich Rahfeld, Michael Wermann, Christoph Parthier, Hans-Ulrich Demuth, David Ruiz-Carillo, Milton T. Stubbs
-
Publication number: 20120045815Abstract: A novel crystal structures of human and murine glutaminyl cyclase (QC, EC 2.3.2.5), methods of preparing the crystals, as well as the use of said crystal structures for identifying inhibitors of human and murine glutaminyl cyclase.Type: ApplicationFiled: August 19, 2011Publication date: February 23, 2012Applicant: PROBIODRUG AGInventors: Stephan Schilling, Jens-Ulrich Rahfeld, Birgit Koch, Michael Wermann, Christoph Parthier, David Ruiz-Carillo, Milton T. Stubbs
-
Publication number: 20100125086Abstract: The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase-like protein (QPCTL), and the use thereof for the treatment and/or prevention of an inflammatory disease or disorder selected from the group consisting of (a) chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis; (b) other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis, Guillain-Barré syndrome, chronic inflammatory demyelinising polyradiculoneuropathy and multiple sclerosis; (c) neuroinflammation; and (d) neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, and Familial Danish Dementia, which may result from neuroinflammation.Type: ApplicationFiled: September 4, 2009Publication date: May 20, 2010Applicant: PROBIODRUG AGInventors: Hans-Ulrich Demuth, Stephan Schilling, Michael Wermann, Holger Cynis, Astrid Kehlen, Daniel Friedrich, Torsten Hoffmann, Kathrin Gans, Jens-Ulrich Rahfeld, Ulrich Heiser, Michael Almstetter, Robert Sommer, Ulf-Torsten Gaertner, Antje Hamann, Michael Thormann, Andreas Tremel
-
Publication number: 20080200567Abstract: A transgenic non-human animal, in particular a transgenic mouse, encoding Qpct proteins which have been implicated in Qpct-related diseases. Also disclosed are cells and cell lines comprising transgenes encoding for Qpct. Further disclosed are methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.Type: ApplicationFiled: January 18, 2008Publication date: August 21, 2008Applicant: PROBIODRUG AGInventors: Stephan Schilling, Holger Cynis, Torsten Hoffmann, Hans-Ulrich Demuth, Michael Wermann, Katrin Schulz